Long-term side effects of Wegovy: what the evidence shows

Step 1, the first weeks: what to expect as your body adjusts

Wegovy's dose schedule is gradual by design. Treatment begins at 0.25mg weekly, moving up in roughly four-weekly steps, because slower titration reduces the intensity of gastrointestinal effects. In the STEP 1 trial (68 weeks, semaglutide 2.4mg versus placebo, published in the New England Journal of Medicine) nausea was the most commonly reported side effect, affecting a substantial proportion of participants, but most cases were mild to moderate and settled without stopping treatment.

The practical reality in those early weeks: nausea tends to peak in the hours after the injection and improve day by day. Keeping the pen in the fridge door and injecting consistently on the same morning each week helps with routine; some people find injecting before bed reduces how much the nausea interrupts their day. Constipation and loose stools can trade places as the dose rises. Staying well hydrated and keeping fibre intake steady makes a measurable difference, though personal plans are best agreed with your prescriber.

Headache, fatigue and injection-site redness are reported less often but do occur, particularly during the early dose increases. These are described in detail in the NHS patient information for semaglutide and are worth reading before you start.

Step 2, months three to six: what tends to persist and what fades

For most people, the worst of the nausea has eased by month three. The NHS medicines page for semaglutide notes that gastrointestinal effects generally improve as the body adapts to the medicine. What can persist longer is a change in relationship with food, reduced appetite, stronger satiety signals, and sometimes a heightened sensitivity to fatty or rich meals.

Gallbladder issues are worth knowing about. Rapid or significant weight loss of any cause can increase the risk of gallstones, and GLP-1 medicines add a modest additional factor. Symptoms to watch for include pain in the upper right abdomen, particularly after eating, which should be discussed with a doctor rather than managed at home.

Fatigue can continue for some people, though it often reflects the body adjusting to a lower calorie intake rather than a direct drug effect. Ensuring adequate protein and not cutting calories below a sensible floor is something your prescriber can advise on. Muscle mass preservation matters on any extended weight-loss treatment, and strength-based activity is consistently recommended alongside the medicine.

People with a personal or family history of medullary thyroid carcinoma or a condition called MEN2 should not use semaglutide; the prescriber screens for this at consultation. If any new lump or neck swelling appears during treatment, seek medical advice promptly.

Step 3, extended use: the safety signals regulators are watching

Semaglutide's long-term safety profile continues to be monitored because the medicine carries a Black Triangle (▼) designation from the MHRA, meaning it is subject to additional post-marketing surveillance. That is standard practice for newer medicines and does not indicate a known serious problem, it reflects the regulator's commitment to collecting real-world data beyond what clinical trials captured.

The most significant safety communication in recent years came on 29 January 2026, when the MHRA published a Drug Safety Update for all GLP-1 medicines emphasising acute pancreatitis as an infrequent but serious risk. The signal is not new, but the update asked prescribers and patients to remain alert. Pancreatitis typically presents as severe, persistent pain in the centre or upper abdomen that may spread to the back; it can occur with or without vomiting. If that happens, stop eating and seek urgent medical attention rather than waiting to see if it resolves.

For a broader picture of what questions to ask before committing to an extended course, the long-term risks of Wegovy page covers the evidence in more depth. There is also a separate discussion on whether Wegovy is considered safe for long-term use, drawing on current NICE and MHRA positions. If you are weighing up ongoing treatment, it is also worth reading what the long-term side effects of Wegovy are, as well as considering whether Wegovy has long-term side effects that could affect your decision, and our separate page looking at whether there are long-term side effects of Wegovy draws on the latest available evidence.

When to get medical help, and how to report side effects

Most side effects from Wegovy are manageable and do not need emergency care. Some do. Seek prompt medical attention for any of the following: severe abdominal pain that is persistent or radiates to the back; signs of an allergic reaction such as facial swelling, difficulty breathing or a widespread rash; symptoms of gallbladder trouble; signs of dehydration after prolonged vomiting or diarrhoea (dark urine, dizziness, unable to keep fluids down); or any new or worsening mental health symptoms, including low mood or thoughts of self-harm.

If you notice something unexpected during treatment that you think may be related to Wegovy, you can report it directly via the MHRA Yellow Card scheme. This applies to patients as well as healthcare professionals. Real-world reports actively inform how the regulator updates its guidance, your experience is part of the evidence base.

At nume, every repeat prescription involves a clinical review, not a rubber stamp. If your side effects have changed or a new symptom has appeared, that is exactly the moment to raise it. Our prescribers discuss both suitability and safety as part of your consultation, so nothing gets glossed over. You can read more about how we approach aftercare on our about us page, or explore the broader Wegovy side effects overview for the full picture. If you are ready to talk through whether treatment is right for you, start your free consultation and a GPhC-registered prescriber will review your answers the same day.